Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial

NCT05701436 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

144

Enrollment

OTHER

Sponsor class

Conditions

Liver, Cancer of, Primary Resectable

Interventions

DRUG: Oxaliplatin
DRUG: Doxorubicin
DRUG: Lobaplatin
DRUG: Cisplatin
DRUG: Oxaliplatin, Leucovorin, fluorouracil
DRUG: Lobaplatin, Raltitrexed

Sponsor

Zhujiang Hospital